# Cancer Center Support Grant > **NIH NIH P30** · RBHS -CANCER INSTITUTE OF NEW JERSEY · 2021 · $3,025,267 ## Abstract RESEARCH PLAN – RUTGERS CANCER INSTITUTE OF NEW JERSEY OVERALL PROJECT SUMMARY/ABSTRACT The Rutgers Cancer Institute of New Jersey (CINJ) is a matrix/consortium (with Princeton University) and New Jersey’s only NCI-designated Comprehensive Cancer Center, serving a diverse population of 8.9 million people. CINJ focused the strengths and resources of the major research institutions in NJ on addressing the cancer burden in its catchment area (NJ). The rapid trajectory of CINJ’s growth validated the initial vision that one of the Nation’s largest public universities of the health sciences would rapidly bring forth an NCI-designated Cancer Center. CINJ has 227 members (206 Rutgers, 19 Princeton, and 2 collaborating). The State Cancer Registry and Surveillance, Epidemiology, and End Results (SEER) Program was moved to CINJ in 2011, and as a result of state legislation in 2013, CINJ became an independent institute of Rutgers University, optimizing CINJ’s potential for growth, transdisciplinary collaboration, and impact across the catchment area. In FY2018, CINJ received over $68 million in support from Rutgers and Princeton, the State, the Health System, and philanthropy. Direct peer-reviewed support increased ~16%. Members published 3,664 cancer focused publications since 2011 (20% inter- and 24% intra-programmatic, 55% inter-institutional). In January 2017, Steven K. Libutti was appointed Director of CINJ and Vice Chancellor for Cancer Programs for Rutgers Biomedical and Health Sciences (RBHS). In a strategic partnership with the RWJBarnabas Health System, Libutti was named Senior Vice President for Oncology Services. CINJ is now positioned to coordinate both cancer research and care throughout its catchment area. An iterative strategic planning process resulted in reorganization of research Programs to increase collaborations, cancer focus, translation, and investigator-initiated clinical trials. These five Programs are: 1) Cancer Metabolism and Growth (CMG), 2) Genomic Instability and Cancer Genetics (GICG), 3) Cancer Pharmacology (CP), 4) Clinical Investigations and Precision Therapeutics (CIPT), and 5) Cancer Prevention and Control (CPC). These Programs are supported by eight shared resources (Biomedical Informatics, Biometrics, Biorepository and Histopathology Services, Comprehensive Genomics, Flow Cytometry/Cell Sorting, Genome Editing, Metabolomics, and Research Pharmacy), with two developing shared resources (Immune Monitoring, Small Molecule Screening). The Statewide authority of CINJ derives from its status as the only NCI-designated Cancer Center; extensive and direct support by the State of New Jersey to serve as the State’s oncology resource; opportunities to conduct translational and population research within the most diverse and densely populated State in the nation; and the synergistic opportunities for collaboration across outstanding research institutions. This supports CINJ’s mission to reduce the burden of cancer in its catchment ... ## Key facts - **NIH application ID:** 10112832 - **Project number:** 5P30CA072720-22 - **Recipient organization:** RBHS -CANCER INSTITUTE OF NEW JERSEY - **Principal Investigator:** STEVEN K. LIBUTTI - **Activity code:** P30 (R01, R21, SBIR, etc.) - **Funding institute:** NIH - **Fiscal year:** 2021 - **Award amount:** $3,025,267 - **Award type:** 5 - **Project period:** 1997-03-01 → 2024-02-29 ## Primary source NIH RePORTER: https://reporter.nih.gov/project-details/10112832 ## Citation > US National Institutes of Health, RePORTER application 10112832, Cancer Center Support Grant (5P30CA072720-22). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10112832. Licensed CC0. --- *[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*